PARP inhibitor
Sponsors
Hellenic Cooperative Oncology Group, University Hospital, Caen, Xiaoxiang Chen, Shanghai Gynecologic Oncology Group, Tianjin Medical University Cancer Institute and Hospital
Conditions
Breast CancerCancerFallopian Tube CancerFallopian Tube CancersHRDHigh Risk Prostate CancerIntense Endocrine TherapyLocally Advanced Prostate Cancer
Phase 2
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
RecruitingNCT05200260
Start: 2022-07-13End: 2027-06-30Target: 220Updated: 2025-02-10
PD1 and PARP for Maintenance Therapy in NSLLC
NCT05392686
Start: 2022-06-20End: 2025-04-01Target: 52Updated: 2022-05-26
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
RecruitingNCT05406999
Start: 2020-02-01End: 2030-06-30Target: 900Updated: 2022-08-16
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
RecruitingNCT06145308
Start: 2023-08-15End: 2028-07-10Target: 39Updated: 2026-04-02
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
RecruitingNCT07117630
Start: 2025-09-25End: 2027-12-01Target: 60Updated: 2026-07-13
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
RecruitingNCT07472140
Start: 2025-07-01End: 2033-06-30Target: 120Updated: 2026-03-16
Unknown Phase
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
NCT04724031
Start: 2019-11-01End: 2023-09-30Target: 150Updated: 2023-03-14
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
CompletedNCT04774627
Start: 2021-02-07End: 2021-03-24Updated: 2021-09-23
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091
Start: 2021-09-15End: 2023-09-30Target: 100Updated: 2021-09-14